Apellis Pharmaceuticals, Inc. (APLS)
APLS Stock Price Chart
Explore Apellis Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze APLS price movements and trends.
APLS Company Profile
Discover essential business fundamentals and corporate details for Apellis Pharmaceuticals, Inc. (APLS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Nov 2017
Employees
705.00
Website
https://www.apellis.comCEO
Cedric Francois
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Financial Timeline
Browse a chronological timeline of Apellis Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.73.
Earnings released on 31 Jul 2025
EPS came in at -$0.33 surpassing the estimated -$0.44 by +25.00%, while revenue for the quarter reached $178.49M , missing expectations by -52.11%.
Earnings released on 7 May 2025
EPS came in at -$0.74 falling short of the estimated -$0.36 by -105.56%, while revenue for the quarter reached $166.80M , missing expectations by -20.29%.
Earnings released on 28 Feb 2025
EPS came in at -$0.29 surpassing the estimated -$0.37 by +21.62%, while revenue for the quarter reached $212.53M , beating expectations by +6.74%.
Earnings released on 5 Nov 2024
EPS came in at -$0.46 falling short of the estimated -$0.32 by -43.75%, while revenue for the quarter reached $196.83M , beating expectations by +2.56%.
Earnings released on 1 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $199.69M , beating expectations by +4.51%.
Earnings released on 7 May 2024
EPS came in at -$0.54 matching the estimated -$0.54, while revenue for the quarter reached $172.33M , beating expectations by +5.49%.
Earnings released on 27 Feb 2024
EPS came in at -$0.73 falling short of the estimated -$0.66 by -10.61%, while revenue for the quarter reached $146.38M , beating expectations by +1.94%.
Earnings released on 1 Nov 2023
EPS came in at -$1.17 falling short of the estimated -$0.84 by -39.29%, while revenue for the quarter reached $99.18M , missing expectations by -0.56%.
Earnings released on 31 Jul 2023
EPS came in at -$1.02 surpassing the estimated -$1.35 by +24.44%, while revenue for the quarter reached $94.97M , beating expectations by +17.07%.
Earnings released on 4 May 2023
EPS came in at -$1.56 falling short of the estimated -$1.42 by -9.86%, while revenue for the quarter reached $44.85M , beating expectations by +71.82%.
Earnings released on 21 Feb 2023
EPS came in at -$1.50 surpassing the estimated -$1.65 by +9.09%, while revenue for the quarter reached $22.66M , missing expectations by -7.16%.
Earnings released on 7 Nov 2022
EPS came in at -$1.75 falling short of the estimated -$1.48 by -18.24%, while revenue for the quarter reached $22.06M , beating expectations by +2.15%.
Earnings released on 8 Aug 2022
EPS came in at -$1.46 falling short of the estimated -$1.43 by -2.10%, while revenue for the quarter reached $16.32M , missing expectations by -3.68%.
Earnings released on 4 May 2022
EPS came in at -$1.42 falling short of the estimated -$1.36 by -4.41%, while revenue for the quarter reached $14.38M , beating expectations by +14.38%.
Earnings released on 28 Feb 2022
EPS came in at -$1.61 falling short of the estimated -$1.32 by -21.97%, while revenue for the quarter reached $60.29M , beating expectations by +586.19%.
Earnings released on 8 Nov 2021
EPS came in at -$2.28 falling short of the estimated -$1.73 by -31.79%, while revenue for the quarter reached $5.65M , missing expectations by -59.59%.
Earnings released on 9 Aug 2021
EPS came in at -$2.72 falling short of the estimated -$1.70 by -60.00%, while revenue for the quarter reached $623.00K , meeting expectations.
Earnings released on 28 Apr 2021
EPS came in at -$2.32 falling short of the estimated -$1.69 by -37.28%.
Earnings released on 25 Feb 2021
EPS came in at $0.93 surpassing the estimated -$0.75 by +224.00%, while revenue for the quarter reached $250.00M , beating expectations by +160.17%.
Earnings released on 2 Nov 2020
EPS came in at -$1.79 falling short of the estimated -$1.53 by -16.99%, while revenue for the quarter reached $646.00K , beating expectations by +13.29%.
APLS Stock Performance
Access detailed APLS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.